Pfizer CMO announces plans to retire; Bayer hit with bad news about Trasylol;

> Pfizer Chief Medical Officer Joe Feczko will retire in a few months after a search for his replacement, CEO Jeff Kindler announced to employees yesterday. Report

> On the same day that a study showed that Bayer's anti-bleeding drug Trasylol was linked with a higher risk of death than alternative drugs were, the company learned it had been slapped with a lawsuit from a woman alleging her husband died because Trasylol was used in his bypass surgery. Report

> Despite concerns expressed by some doctors and patients that generics are inferior products, there is no evidence brand-name meds are clinically superior, according to a meta-analysis of 47 studies of various cardiovascular drugs published in JAMA. Report

> A study of Merck's cervical cancer vaccine Gardasil found that allergic reactions were uncommon and most young women can tolerate subsequent doses, Australian researchers said on Wednesday. Report

> Drugs giant GlaxoSmithKline has announced 200 jobs will be axed at its factory in County Durham, Ireland, over the next 12 to 18 months. Report

> Japanese pharma giant Eisai is creating more than 500 jobs in an expansion nearing completion in Hatfield, England. Report

> Bristol-Myers Squibb will cut the work force at its DeWitt, New York, plant 5 percent by the end of the year as part of its ongoing restructuring, the company confirmed today. Report

> Irish-based Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson that has offices in Yardley, said today that it has signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals Limited of India to distribute an HIV drug in India. Report

> Ranbaxy Laboratories, India's biggest drug maker, said it is partnering with U.S. drug firm BioPro Pharmaceuticals to sell the latter’s brain tumor drug Gliadel Wafer in the country. Report

> MSD Pharmaceuticals, a subsidiary of Merck & Co, plans to launch its branded drugs in India at lower prices than those Merck charges in developed countries, a company official said. Report

> Chennai, India-based drug manufacturer Orchid Chemicals & Pharmaceuticals got the FDA nod to market the anti-epilepsy drug Divalproex Sodium. Report

> Newron Pharmaceuticals has lined up new financing to get itself through the current economic crisis. Report

> Goldman Sachs says it is ready to start funneling hundreds of millions of dollars into a new 'hybrid' R&D model that will be used to advance early and mid-stage drugs in the biopharma pipeline. Report

> Pozen has taken another step toward the regulatory approval of a new arthritis treatment. The Chapel Hill, NC biotech says that PN 400--which is partnered with AstraZeneca--produced new data supporting its efficacy and hit its endpoints in two studies. Report

> Catalyst Biosciences has raised a hefty $40.4 million in a Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors. Report

> Germany's Evotec AG has forged a three-year drug discovery alliance with Novartis that is worth up to $28 million in fees and milestones. Report

> Despite recent setbacks in the search for a new AIDS vaccine, developers are continuing to report fresh progress in the field. Report

> A study of 450 people given Vanda Pharmaceuticals' experimental sleep drug tasimelteon demonstrated that the therapy can swiftly reset a body's circadian rhythm, offering a potential new treatment for people who suffer from jet lag or the effects of a night shift schedule. Report

> Are vaccinations bad for business? That's what some doctors are concerned about. Report

And Finally... Patients who do not initially respond to standard drug therapy for treatment of hepatitis C are unlikely to respond to long-term maintenance therapy as well, according to a new study. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.